Chromium Picolinate Pcos


Written by Joyce Smith, Staff Writer. Women with Polycystic Ovarian Syndrome who supplemented with chromium picolinate for 8 weeks experienced significantly less alopecia, hirsutism, acne and had reduced levels of inflammation and oxidative stress compared to those PCOS women who did not take chromium.

Polycystic ovary syndrome (PCOS) is a common endocrine system disorder that affects 6-8% of women of reproductive age worldwide 1. People with PCOS may have infrequent or prolonged menstrual periods, alopecia (baldness), hirsutism (excess hair growth on the face and body), acne, insulin resistance, obesity and polycystic ovaries.2 Some studies have suggested that people with PCOS may have hyperglycemia, impaired insulin metabolism, and an abundance of adipose tissue, all of which contribute to free radical formation and reactive oxygen species (ROS) and increase the biomarkers for inflammation and oxidative stress 3.

Other studies have suggested that people with increased levels of inflammation, particularly due to elevated C-reactive protein (CPR) and interleukin 18 (IL-18) 4, may have an increased risk of developing atherosclerosis because of accelerated endothelium dysfunction 5.

Chromium polynicotinate appears to have a beneficial effect on glucose metabolism in people with type 2 diabetes. Chromium picolinate is another generally recommended form of chromium, although there is some suggestion that high doses could be mildly mutagenic (cause changes in DNA). Chromium picolinate, up to 1000 mcg/day, improves insulin resistance. Cinnamon improves insulin resistance. One small study looking specifically at its use in women with PCOS found that 1.5 gm/day improved menstrual regularity. Chromium picolinate, up to 1000 mcg/day, improves insulin resistance. Cinnamon improves insulin resistance. One small study looking specifically at its use in women with PCOS found that 1.5 gm/day improved menstrual regularity.

Because of limited available research, researchers chose to investigate the effects of chromium supplementation on endocrine profiles, inflammatory cytokines, and biomarkers of oxidative stress among women with PCOS.

This randomized, double- blind, placebo-controlled clinical trial consisted of two groups of 60 PCOS women (18-48 years of age) who received either 200 mcg of chromium picolinate supplements daily (n=30) or placebo (n=30) for 8 weeks. Three dietary and three physical activity records were completed at weeks3, 5, and 7 of treatment. Participants kept three-day food diaries which were used to compute their nutrient intakes.

Endocrine profiles were quantified on all patients from fasting blood samples taken before and after 8 weeks of chromium supplementation. These included serum prolactin, follicular-stimulating hormone (FSH), and luteinizing hormone (LH) concentrations, serum free testosterone, dehydroepiandrosterone (DHEA), and 17-OH progesterone concentrations.

Also recorded were high sensitivity C-reactive protein (hs-CRP), a measure of inflammation and the following biomarkers of oxidative stress: nitric oxide (NO) 6, Total Oxygen Capacity (TAC) 7, glutathione (GSH), and malondialdehyde (MDA) 89.

Anthropometric measures were documented, including height and weight, to assess body shape, size and composition. The presence and degree of hirsutism 10, alopecia 11, and acne 12 were also documented. A P value of < 0.05 was considered statistically significant.

After 8 weeks of intervention, the chromium group had a greater pregnancy rate (P=0.08) and decreased alopecia (baldness) (P=0.22); however, neither reached significance.

The chromium group had a significant reduction in acne (P=0.04), hirsutism (P=0.002), serum hs-CRP (P=0.02), plasma MDA (P<0.001), and a significant rise in TAC concentrations (P<0.001) compared to the placebo group.

Summary of Effects of Chromium Supplementation
Chromium GroupPlacebo p-value
Pregnancy Rate16.7 % (5/30) 3.3 % (1/30),P=0.08*
Serum hs-CPR(−717.0 ± 1496.1ng/mL) (+227.1 ± 1669.6 ng/mL)P=0.02
Plasma MDA(−0.1 ± 0.7 μmol/L) (+1.1 ± 1.5 μmol/L)P<0.001
TAC (+250.7 ± 265.2mmol/L)(+13.0 ± 201.6 mmol/L)P<0.001
Hirsutism(−1.8 ± 2.5)(-0.2 ± 0.8)P=0.002
Acne20.0 % 3.3 %P=0.04
NO, GSH, Endocrine profile*No significant changes

There were no significant changes in endocrine profiles and NO and GSH levels following chromium supplementation.

Chromium and pcosPicolinate

Unfortunately the effects of chromium supplementation on serum chromium concentrations were not included in the panel of tests because of limited funds. Also, patients who had impaired glucose tolerance and insulin resistance might have added value to the study had they not been excluded from it. Overall, chromium supplementation had “beneficial effects on acne, hirsutism, hs-CRP, TAC, and MDA levels” but had no effect on endocrine profiles, NO, and GSH.

Chromium picolinate dose for pcos

Holistic Pcos Treatment

Source: Mehri Jamilian M., Bahmani F., Siavashani M.A., et al. The Effects of Chromium Supplementation on Endocrine Profiles, Biomarkers of Inflammation, and Oxidative Stress in Women with Polycystic Ovary Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Endocrinology (2015), 82, 885–891; doi: 10.1111/cen.12699

Chromium Picolinate Pcos Symptoms

© 2014 John Wiley & Sons Ltd


Posted October 24, 2016.


Natural Treatment Polycystic Ovarian Syndrome

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2745-2749.
  2. Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T, Asemi Z. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double‐blind, placebo‐controlled trial. Clinical endocrinology. 2015;82(6):885-891.
  3. Hyderali BN, Mala K. Oxidative stress and cardiovascular complications in polycystic ovarian syndrome. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2015;191:15-22.
  4. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction update. 2012;18(2):112-126.
  5. Kaya C, Pabuccu R, Berker B, Satıroglu H. Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors. Fertility and sterility. 2010;93(4):1200-1207.
  6. Tatsch E, Bochi GV, da Silva Pereira R, et al. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clinical biochemistry. 2011;44(4):348-350.
  7. Benzie IF, Strain J. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical biochemistry. 1996;239(1):70-76.
  8. Beutler E, Gelbart T. Plasma glutathione in health and in patients with malignant disease. The Journal of laboratory and clinical medicine. 1985;105(5):581-584.
  9. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radical Biology and Medicine. 1990;9(6):515-540.
  10. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. American journal of obstetrics and gynecology. 1981;140(7):815-830.
  11. Olsen E, Hordinsky M, McDonald-Hull S, et al. Alopecia areata investigational assessment guidelines. Journal of the American Academy of Dermatology. 1999;40(2):242-246.
  12. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and sterility. 2000;73(6):1149-1154.